Martin Shkreli, the former pharmaceutical executive who was previously barred from the industry, is facing new scrutiny from the Federal Trade Commission (FTC). The agency is investigating claims that Shkreli violated the terms of a lifetime ban imposed on him following a 2022 court ruling. The controversy centers on a recent livestream in which Shkreli discussed his interest in biotech investments, explicitly stating, "I can always find a couple of biotech stocks to smoke."

The FTC’s lifetime ban was originally implemented to prevent Shkreli from participating in the pharmaceutical industry, including roles as an officer or director of a public company, following his conviction for securities fraud and his involvement in price-gouging schemes. While Shkreli has maintained a public presence online since his release from prison, this specific comment has drawn the attention of regulators who are tasked with enforcing the terms of his settlement.

There is currently no consensus on the legal implications of the livestream. While the FTC has signaled that it is reviewing the incident, Shkreli’s representatives have not yet provided a formal defense regarding whether discussing stock market activity constitutes a violation of his specific industry prohibitions. The situation remains an ongoing regulatory matter as authorities determine if his commentary crosses the line from personal opinion into prohibited professional activity.